Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 653048 H3PO4 high dose capsuleDrug: PlaceboDrug: BI 653048 H3PO4 low dose capsuleDrug: BI 653048 H3PO4 solution
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT02217644
Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02217514
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 140
- Registration Number
- NCT02217631
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Low dose of BIBW 2948 BS for oral inhalationDrug: Medium dose of BIBW 2948 BS for oral inhalationDrug: High dose of BIBW 2948 BS for oral inhalationDrug: Placebo
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02216461
Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: BIRB 796 BS, low doseDrug: BIRB 796 BS, high doseDrug: Placebo
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 170
- Registration Number
- NCT02214888
Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 269
- Registration Number
- NCT02215798
Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 11634 ER formulation CDrug: BI 11634 ER formulation MDrug: BI 11634 IR tabletDrug: BI 11634 ER formulation ADrug: BI 11634 ER formulation B
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT02214953
Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02214992
Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02215031
Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02214979